United Therapeutics Corp. (UTHR)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 0 |
| Ownership rank: | -- |
| % of all portfolios: | 0% |
| History | Portfolio Manager | Activity ▲ | Share change | % change to portfolio | |
| Q4 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 4,361 | 0.01 | |
| Q3 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 47.79% | 3,992 | 0.01 | |
| Q2 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 11.17% | 839 | 0.00 | |
| Q1 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 7,514 | 0.01 | |
| Q1 2020 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 14,781 | 0.02 | |
| Q4 2019 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 15.82% | 2,019 | 0.00 | |
| Q3 2019 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 12,762 | 0.01 | |
| Q3 2017 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 18,720 | 0.03 | |
| Q2 2017 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 3.70% | 720 | 0.00 | |
| Q1 2017 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 25.83% | 6,770 | 0.01 | |
| Q4 2016 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 1.16% | 300 | 0.00 | |
| Q3 2016 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 3.00% | 800 | 0.00 | |
| Q2 2016 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 27.62% | 5,780 | 0.01 | |
| Q1 2016 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 98.01% | 10,360 | 0.02 | |
| Q4 2015 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 9.65% | 930 | 0.00 | |
| Q3 2015 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 155.70% | 5,870 | 0.01 | |
| Q2 2015 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 16.22% | 730 | 0.00 | |
| Q1 2015 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 4,500 | 0.01 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.